Hello Shakey - Don't know why you posted last years news, although we should 

remember there was a reason why Haywood did that bought deal, I feel that 

fruition is coming.  Here is the latest news:

~~ Dimar 

Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual
Global Healthcare Conference - May 16, 2008 3:59PM ET

Live Web Cast Scheduled for May 19 at 10:15 a.m. Eastern Time

Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) today announced
that S. Wayne Kay, Chief Executive Officer, is scheduled to present at the
Rodman & Renshaw 5th Annual Global Healthcare Conference on Monday May
19th at 10:15 a.m. EDT.

A live web cast of the presentation will be available on the Company's Web
site at
http://www.responsebio.com/newsroom_events_calendar_corporate.asp?menu=1&submenu=3
and replays will be available for 14 days starting approximately three
hours after the initial presentation.

About Response Biomedical

Response Biomedical develops, manufactures and markets rapid on-site
diagnostic tests for use with its RAMP(R) Platform for clinical and
environmental applications. RAMP(R) represents a new paradigm in
diagnostics that provides high sensitivity and reliable information in
minutes. It is ideally suited to both point-of-care testing and laboratory
use. The RAMP(R) system consists of a Reader and single-use disposable
test cartridges, and has the potential to be adapted to more than 250
medical and non-medical tests currently performed in laboratories. RAMP(R)
clinical tests are commercially available for the early detection of heart
attack and congestive heart failure.

In late 2006, the Company formed a strategic alliance with 3M Company to
commercialize rapid infectious disease tests. In the non-clinical market, 
RAMP(R) Tests are currently provided for the environmental detection of
West Nile Virus, and Biodefense applications including the rapid on-site
detection of anthrax, smallpox, ricin and botulinum toxin. Several other
product applications are under development. Response has achieved CE
Marking and its Quality Management System is registered to ISO 13485: 2003
and ISO 9001: 2000.

Response Biomedical is a publicly traded company, listed on the TSX under
the trading symbol "RBM" and quoted on the OTC Bulletin Board under the
symbol "RPBIF". For further information, please visit the Company's
website at www.responsebio.com.

SOURCE: Response Biomedical Corp.

Response Biomedical Contacts: Bill Wickson, Manager, Investor Relations,
Response
Biomedical Corporation, Tel (604) 456-6073, Email:
bwickson@responsebio.com; Brian
Korb, Vice President, The Trout Group LLC, Tel: (646) 378-2923, Email:
bkorb@troutgroup.com